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Abstract
Background: Prostate cancer has a variable clinical behaviour with frequently unpredictable outcome. DNA methylation
plays an important role in determining the biology of cancer but prognostic information is scanty. We assessed the
potential of gene-specific DNA methylation changes to predict death from prostate cancer in a cohort of untreated men
in the UK.
Methods: This was a population-based study in which cases were identified from six cancer registries in Great Britain.
DNA was extracted from formalin-fixed paraffin wax-embedded transurethral prostate resection tissues collected during
1990-96 from men with clinically-localised cancer who chose not to be treated for at least 6 months following diagnosis.
The primary end point was death from prostate cancer. Outcomes were determined through medical records and cancer
registry records. Pyrosequencing was used to quantify methylation in 13 candidate genes with established or suggested
roles in cancer. Univariate and multivariate Cox models were used to identify possible predictors for prostate cancer-related
death.
Results: Of 367 men, 99 died from prostate cancer during a median of 9.5 years follow-up (max = 20). Univariately, 12
genes were significantly associated with prostate cancer mortality, hazard ratios ranged between 1.09 and 1.28 per decile
increase in methylation. Stepwise Cox regression modelling suggested that the methylation of genes HSPB1, CCND2 and
DPYS contributed objective prognostic information to Gleason score and PSA with respect to cancer-related death during
follow-up (p = 0.006).
Conclusion: Methylation of 13 genes was analysed in 367 men with localised prostate cancer who were conservatively
treated and stratified with respect to death from prostate cancer and those who survived or died of other causes. Of the
13 genes analysed, differential methylation of HSPB1, CCND2 and DPYS provided independent prognostic information.
Assessment of gene-methylation may provide independent objective information that can be used to segregate prostate
cancers at diagnosis into predicted behavioural groups.
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Background
Prostate cancer is the most common malignancy in men
but a significant proportion of the cases are essentially
harmless and will not result in morbidity or death if left
untreated. Currently the best-available prognostic tool for
routine management is Gleason score [1]. Nevertheless
histopathology has some limitations such as intra- and inter-
observer variability in grading [2] and for needle biopsies
there is additional variability due to difficulty in targeting
cores precisely to the cancerous areas. These sources of vari-
ability lead to quite large differences in the accuracy of diag-
nosis and prognosis. Testing serum for prostate specific
antigen (PSA) has improved early detection and is an in-
creasingly used screening tool, however, its poor specificity in
combination with absence of a highly accurate prognostic
tool may lead to increased numbers of invasive examinations
and biopsies resulting in unnecessary treatment with risk of
morbidity [3-5]. Therefore there is an urgent need for stan-
dardised quantifiable molecular biomarker assays to improve
disease stratification and subsequent management [6].
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DNA methylation (DNAme) is important for normal
development in higher organisms. In the human genome,
the majority of CpG dyads have similar patterns of methy-
lation in normal and cancerous tissues. However, CG rich
regions (so-called CpG islands) covering the promoters
and first exons of over half of human genes often show
highly variable methylation, which is considered of regula-
tory importance [7-9]. Abnormal DNAme contributes to
the occurrence and progression of prostate cancer [10,11].
Development of methylation assays to diagnose and/or
predict disease outcomes in cancer patients undergoing
active follow-up with minimal intervention is topical
[12,13]. In prostate cancer, numerous hypermethylated
genes have been found, with GSTP1, APC1 and RARB
amongst the most frequently reported [14], and hitherto
mainly assessed for diagnostic purposes. The few studies
focusing on the prognostic value of methylation generally
use time to biochemical recurrence after surgical treat-
ment as the primary endpoint, which does not accurately
estimate the potential of the cancer in terms of risk of
death if left untreated [15-17]. Therefore, the primary
purpose of this study was to explore the hypothesis that
methylation testing of specific genes in men with un-
treated clinically-localised prostate cancer contributes ob-
jective information with respect to prostate cancers that
will lead to death during follow-up. The principal object-
ive was to assess the univariate prognostic biomarker
potential of DNA methylation of 13 individual genes and
multivariate combinations of genes, by analysing the asso-
ciation between methylation and death from prostate
cancer as the primary endpoint. The secondary objective
was to determine whether methylation-status improves
prognostic value of current clinical reference variables
(Gleason score and PSA) and finally to investigate mor-
tality predictions of models fitted with variables that
can be measured in serum (i.e. methylation and PSA).
Candidate genes GSTP1, APC, RARB, CCND2, SLIT2,
SFN, SERPINB5, MAL, DPYS, TIG1, HIN1, PDLIM4 and
HSPB1 were investigated because they were earlier re-
ported to be associated with the diagnosis or prognosis
of prostate cancer in addition to a variety of other
cancers [18-23].
Univariate analysis showed that genes assessed individu-
ally were only modest predictors of death from prostate
cancer. However, multivariate analysis revealed that
methylation of DPYS, CCND2 and HSPB1 together added
a substantial amount of prognostic information not cap-
tured by any other measure and therefore may be useful
for improvement of prostate cancer management.
Methods
Study population
388 formalin-fixed paraffin wax-embedded (FFPE) trans-
urethral resection of prostate (TURP) tissues from the
Transatlantic Prostate Group (TAPG) cohort were ran-
domly selected for the current study (Figure 1) [1]. The
TAPG cohort comprises well-characterised men residing
in the United Kingdom who did not receive any treat-
ment for at least 6 months following diagnosis of prostate
cancer. These patients experienced a high rate of prostate
cancer-related death and provided sufficient cases to
establish our endpoint of interest. Briefly, FFPE prostate
cancer tissue blocks were obtained from six cancer regis-
tries in Great Britain. Men were included if they had
clinically localised prostate cancer diagnosed by TURP
between 1990 and 1996 inclusive, and were younger
than 76 years at the time of diagnosis. To focus on
patients likely to have biologically localised disease at
presentation - patients were excluded if 1) treated by
radical prostatectomy, hormones, radio- or chemother-
apy 2) showed objective evidence of metastatic disease
and 3) had a PSA measurement above 100 ng/ml. Pa-
tients who died at or within 6 months of diagnosis were
automatically excluded. Following triage by a single
expert prostate pathologist (DMB) the original histo-
logical TURP specimens were reviewed by a panel of
expert urological pathologists to confirm the diagnosis
and, when necessary, to reassign scores by use of a con-
temporary interpretation of the Gleason scoring system
[24]. The primary endpoint was death from prostate
cancer and outcomes were determined through medical
records and cancer registry records. Where available,
death certificates were reviewed to verify cause of death.
Deaths were divided into two categories: death from pros-
tate cancer and death from other causes, according to
standardised World Health Organisation criteria [25]. Pa-
tients still alive at last follow-up in December 2009 were
censored.
National ethics approval was obtained from the Northern
Multicentre Research Ethics Committee, followed by local
ethics committee approval at each of the collaborating
NHS hospital trusts (Ashford & St. Peter’s, Barnet & Chase
Farm, Brighton and Sussex, Dartford & Gravesham, East &
North Hertfordshire, Eastbourne, Epsom & St. Helier, Essex
Rivers Healthcare, Frimley Park, Greenwich Healthcare,
Guy’s & St Thomas’s, Hammersmith Hospitals, Havering
Hospitals, Hillingdon, King’s Healthcare, Kingston,
Lewisham, Mayday Healthcare, The Medway, Mid Essex
Hospitals; Mid Kent, North West London Hospitals,
Royal Free Hampstead, St Bartholomew’s and The Royal
London Hospitals, Royal Surrey County, Southend, St
George’s London, St Mary’s London, West Hertfordshire,
Worthing & Southlands Hospitals, Airedale, Hull & East
Yorkshire, The Leeds Teaching Hospitals, Heatherwood &
Wexham Park, Milton Keynes, Northampton, Oxford
Radcliffe, Royal Berkshire & Battle, Stoke Mandeville,
Ceredigion and Mid Wales, Conwy & Denbighshire, NE
Wales, Gwent Healthcare, Swansea, Cardiff & Vale, The
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Lothian University Hospitals, North Glasgow University
Hospitals, Royal Liverpool University Hospital.) [1].
DNA isolation and bisulfite conversion
FFPE sections were deparaffinised in xylene by submer-
sion two times for 5 minutes and absolute ethanol three
times for 5 minutes. From each case an H&E stained
section that had been previously annotated for cancerous
and normal areas by an expert pathologist (DMB) was
used as a guide for macrodissection. Depending on esti-
mated tumour tissue size, one to six 5 μm FFPE sections
were dissected [26] and DNA was extracted and converted
as previously described [19].
DNA methylation assay
Our study was conducted following REMARK guidelines
[27]. The primer design, sequences and PCR conditions
were previously optimised and described [19,20]. PCRs
were performed employing the PyroMark PCR kit
(Qiagen, 978703) with standard curves and a converted
DNA equivalent of 1000 cells per sample. Presence of
the correct amplicons was confirmed by the QIAxcel
capillary electrophoresis instrument (Qiagen). Pyromark
and PyroGold reagents (Qiagen, 979009, 979006, 972804)
were used for the pyrosequencing reaction and the raw
pyrogram signals were analysed using the PyroMark Q96
ID system (Qiagen, 9001525) [20].
Statistical methods
The statistical methods were documented in a pre-specified
statistical analysis plan and laboratory testing was blinded
from the clinical variables to minimise bias in the results.
Three to six CpG positions were analysed per gene and
mean methylation of the investigated CpG positions within
each assay was used for all analyses. As clinical stage could
not be obtained for a significant number of patients, it was
completely excluded from our analysis. The Spearman’s rho
correlation coefficient was estimated for methylation levels
of all gene combinations as well as between each gene and
age, PSA score, Gleason score and extent of disease. A
univariate Cox regression model with the primary end-
point death from prostate cancer was fitted for each of
the available clinical variables and each investigated
gene. P-values were adjusted for multiple comparisons
using the Benjamini Hochberg false discovery rate ap-
proach [28]. Stepwise Cox regression models were fitted
using all available variables or combination of selected var-
iables to investigate different clinical circumstances and
then compared by the likelihood ratio (LR) test. Gene
methylation values and clinical variables were analysed as
continuous data in all fitted Cox models. The extent of
disease estimated from the TURP specimens was excluded
in multivariate analysis due to the fact that this variable as
defined in our study (percentage of TURP chips with can-
cer) would either not be available or not be comparable
Figure 1 Consort diagram of TAPG cohort patients enrolled in current study.
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for risk assessment in needle biopsies typical of normal
clinical settings.
Kaplan Meier survival curves were plotted for the
models presented. All applied tests were two-sided and
P-values of ≤0.05 were regarded as statistically signifi-
cant. Statistical analyses were done with STATA 11 and
R 2.12.2.
Results
DNAme of 13 candidate genes – GSTP1, APC, RARB,
CCND2, SLIT2, SFN, SERPINB5, MAL, DPYS, TIG1,
HIN1, PDLIM4 and HSPB1 was measured in 367 men
from the TAPG cohort. 21 patients were excluded after
DNA extraction due to no or poor quality tumour DNA
obtained (Figure 1). The characteristics of the 367 men
are presented in Table 1. Median age was 70.5 years
(range 49.9 – 76, IQR = 5.9), median follow-up was
9.5 years (range 0.7-19.6, IQR = 9.2) and there were 99
deaths from prostate cancer. The DNAme measure-
ments for the different genes were of varying success
rate (94-99%) (Table 2). The distribution of methylation
of each gene was plotted in two groups: men who died
of prostate cancer and censored men who were alive at
the last visit or had died of other causes (Figure 2).
Univariately, methylation of 12 genes was associated to
prostate cancer-specific death (Table 2). Gleason score
was the strongest predictor with the hazard ratio (HR)
2.33 [95% CI 1.99-2.74] for each unit increment (i.e.
Gleason score 4, 5, …10). In comparison, the strongest
among genes, MAL displayed HR 1.28 [95% CI 1.17-1.40]
per 10% increment in methylation (Table 2). To make
clinical variables more comparable to DNAme, the HR for
the PSA (ng/mL), extent of disease (%) and age (year) were
also calculated per 10 unit increments.
Methylation was successfully measured for all 13 genes
in 309 patients including 81 prostate cancer-specific
deaths and this subset was used for the stepwise multi-
variate Cox regression models. To assess clinical utility
of DNAme, mortality prediction by models investigating
four distinct sets of variables were considered: A)
Methylation of 13 genes, B) Molecular variables (gene
methylation and PSA), C) Current clinical standard
(Gleason score and PSA) and D) All variables (includ-
ing the interaction between the gene methylation and
the clinical variables). Model D was the best multivariate
model with LR χ2(6df) = 125.7, which included Gleason score,
PSA, DPYS, HSPB1, interaction term [HSPB1xGleason
score] and CCND2 (Table 3). In comparison, model C was
the next best model with LR χ2 (2df) = 111.4. Model B was
formed of PSA and methylation of DPYS, HSPB1, MAL
and TIG1 with LR χ2(5df) = 76 and the gene-only model
comprised: DPYS, GSTP1, and MAL with LR χ2(3df) = 49.4
(Table 3). As a higher likelihood ratio χ2 indicates a better
model. The Δχ2(4df ) between model D and C was 14.3
(P =0.006), which shows that a set of variables corre-
sponding to differential DNA methylation of the iden-
tified genes adds a statistically significant amount of
information to the risk prediction of current clinical
reference standard (Table 3).
The risk scores obtained from the linear predictors of
the four models were categorised into low, medium and
high risk groups using the 25% and 75% quantiles and
Kaplan Meier survivor curves were plotted (Figure 3).
The proportion of prostate cancer-specific deaths in
each of the groups low, median and high were calculated
for the different models (Additional file 1: Table S1)
expanding the information from the curves. Kaplan Meier
survivor curves illustrated that although the models in-
cluding Gleason score are best, use of PSA in combination
with gene methylation provided a similar amount of infor-
mation, particularly for identifying patients at highest risk
(Figure 3B).
To explore the effect of competing risks we fitted a
proportional hazards model which assesses the effect of
covariates on the sub-distribution of a particular type of
Table 1 Characteristics of 367 analysed men from TAPG
cohort
Characteristics No. (%) of patients
All patients 367
DPCaa Yes 99 (27)
No 268 (73)
Gleason score Gleason 4 3 (0.8)
Gleason 5 17 (4.6)
Gleason 6 171 (46.6)
Gleason 7 84 (22.9)
Gleason 8 43 (11.7)
Gleason 9 43 (11.7)
Gleason 10 6 (1.6)
PSA score ≤4 138 (37.6)
4 - ≤10 76 (20.7)
10 - ≤25 73 (19.9)
25 - ≤50 54 (14.7)
50 - 100 26 (7.1)
Extent of Disease ≤0.06 108 (29.4)
0.06 - ≤0.20 95 (25.9)
0.20 - ≤0.40 55 (15.0)
0.40 - ≤0.75 44 (12.0)
> 0.75 65 (17.7)
Age at diagnosis ≤54 3 (0.8)
>54 - 64 49 (13.4)
>64 - 74 253 (68.9)
>74 - 76 62 (16.9)
aDPCa = death from prostate cancer.
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Table 2 Univariate Cox regression of 13 genes and available clinical variables
HRa (95% CI) LRb χ2 Adjustedc P-value Harrell’s c-index Total Nod Event Noe
Gleason score 2.33 (1.99, 2.73) 105.3 2.2*10−16 0.79 367 99
Extent of disease 1.27 (1.21, 1.34) 80.1 2.2*10−16 0.76 367 99
PSA 1.36 (1.28, 1.45) 68.9 6.3*10−16 0.76 367 99
Age 1.04 (1.00, 1.09) 3.2 0.08 0.52 367 99
MAL 1.28 (1.17, 1.40) 25.4 2.0*10−6 0.64 352 95
DPYS 1.20 (1.12, 1.29) 24.2 2.9*10−6 0.65 344 95
TIG1 1.25 (1.14, 1.36) 20.9 1.4*10−5 0.65 350 90
GSTP1 1.17 (1.08, 1.26) 16.4 1.2*10−4 0.62 357 98
APC 1.18 (1.08, 1.29) 10.9 0.002 0.61 365 99
PDLIM4 1.16 (1.06, 1.26) 10.9 0.002 0.60 365 98
RARB 1.13 (1.04, 1.24) 7.7 0.01 0.60 351 98
SLIT2 1.17 (1.05, 1.31) 6.6 0.016 0.58 350 94
SFN 1.13 (1.02, 1.25) 5.8 0.023 0.57 363 99
CCND2 1.12 (1.02, 1.23) 5.2 0.029 0.56 364 99
HIN1 1.09 (1.01, 1.18) 5.1 0.029 0.59 350 97
HSPB1 1.12 (1.02, 1.22) 5.0 0.029 0.52 349 91
SERPINB5 0.95 (0.83, 1.08) 0.7 0.408 0.53 357 95
aThe hazard ratios were calculated per 10 units increase in age, PSA, extent of disease and gene methylation while it is per unit increase in Gleason score, i.e. 4
through 10.
bLR = likelihood ratio test.
cThe Benjamin and Hochberg step-up procedure for controlling false discovery rate (FDR) was applied with FDR of 5%.
dThe total number of patients for which DNAme was successfully measured. The clinical variables were available for all men included in the study.
eThe number of patients for which a DNAme result was obtained and who died of prostate cancer.
Figure 2 DNA methylation in two groups of interest. Comparison and distribution of DNAme percent (y-axis) in each of the investigated
genes to the clinical variables in men who died of prostate cancer (grey box) compared to the censored men who were alive at the last visit or
died of other causes (white box). Whiskers of the boxplot mark the 5th and 95th percentiles, the box 25th percentile, median and 75 percentile,
while extreme values are shown by (•). For graphical presentation, all Gleason score values were scaled by a factor of 10.
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Table 3 Multivariate Cox models
Model A:Gene-Only Model B:Genes + PSA Model C:Gleason + PSA Model D:Final model
Variable HR (95% CI) χ2 P-value HR (95% CI) χ2 P-value HR (95% CI) χ2 P-value HR (95% CI) χ2 P-value
Gleason -b - - - - - 2.20 (1.82, 2.67) 66.3 3.3*10−16 2.72 (2.09, 3.53) 56.3 6.4*10−14
PSA - - - 1.27 (1.18, 1.38) 36.5 1.5*10−9 1.27 (1.17, 1.37) 34.9 3.5*10−9 1.23 (1.13, 1.34) 24.7 6.7*10−7
DPYS 1.12 (1.02, 1.24) 5.8 0.016 1.12 (1.02, 1.24) 5.3 0.021 - - - 1.13 (1.03, 1.25) 6.4 0.012
HSPB1 0.88 (0.78, 0.99) 4.6 0.032 - - - 2.39 (1.15, 4.97) 5.5 0.019
Gleason x HSPB1a - - - - - - - - - 0.89 (0.81, 0.97) 6.2 0.012
CCND2 - - - 0.86 (0.75, 0.98) 5.1 0.024
MAL 1.19 (1.05, 1.34) 7.6 0.006 1.17 (1.03, 1.34) 5.7 0.017 - - -
GSTP1 1.15 (1.03, 1.27) 6.6 0.010 - - -
TIG1 1.15 (1.03, 1.27) 6.5 0.011 - - -
LR χ2 (df) 49.4 (3) 76.6 (5) 111.4 (2) 125.6 (6)
Harrell’s c-index (se) 0.716 (0.034) 0.771 (0.034) 0.831 (0.034) 0.835 (0.034)
Gönen & Heller’s
c-indexc (se)
0.696 (0.022) 0.702 (0.019) 0.738 (0.016) 0.757 (0.017)
a)Cross-product of Gleason score multiplied by HSPB1 methylation. For construction of a full model, all clinical variables and genes were included as well as interaction terms between each of the genes and the
variables. The only significant interaction was found for Gleason score and HSPB1.
b)Variable not included in model.
c)The Gönen & Heller’s c-index is independent of the degree of censoring and is somewhat comparable to an area under the curve corresponding to a plot of the sensitivity versus positive predictive value of
the predictor.
(df) = degrees of freedom.
(se) = standard error.
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failure in a competing risks setting (performed by means
of the R-package cmprsk). A stepwise model selection
analysis was performed, yielding the same markers that
were selected by stepwise model selection using an or-
dinary Cox model (data not shown).
As an internal validation of the improvement of model
D compared to model C, intended to correct for statis-
tical optimism, we used the original data (n = 309, ex-
cluding missing values) on survival time, event and
predictors. Models were fitted in the bootstrap sample
(with replacement) and a backward stepwise method
was applied at significance level 0.05 for a predictor to
be kept in a model. The final selected Cox model was
fitted in the bootstrap sample and applied without
change to the original sample. The process was repeated
for B = 1000 bootstrap replications to obtain an average
optimism, which was subtracted from the fit value of the
final models [29]. We were primarily interested in the
resulting optimism corrected Gönen & Heller’s c-index
because this index is independent of the degree of
censoring and more accurately reflects diagnostically
important differences; the c-index for Model C was
0.737 and for model D was 0.741, showing an internally
validated small improvement for a classifier that includes
the DNA methylation biomarkers.
Discussion
This study has revealed several biomarkers of promising
prognostic value in prostate cancer following measure-
ment of the methylation of particular gene promoters/
first exons. In the univariate analysis, 12 of the 13 inves-
tigated genes with HR ranging between 1.09 and 1.28
per a decile increase in DNAme (Table 2) were signifi-
cantly associated to prostate cancer-specific death. While
Gleason score by specialist prostate pathologists employ-
ing strict criteria remained the best available prognostic
variable (LR χ2 = 105.3), morphological appearance is a
vectorial parameter resulting from the interaction of sev-
eral individual key genes or their products that contribute
significantly to clinical outcome. In the comprehensive
multivariate analysis, the model with best prognostic abil-
ity included Gleason score, PSA, HSPB1, [HSPB1xGleason
Figure 3 Kaplan Meier survival analysis curves for the fitted models. A) DPYS, GSTP1 and MAL, B) PSA and DNAme of DPYS, HSPB1, MAL and
TIG1, C) Gleason score and PSA and D) the full model with Gleason score, PSA, DPYS, HSPB1, [HSPB1xGleason score] and CCND2. Low (solid line),
medium (dashed line) and high risk groups (dotted line) were separated by the 25% and 75% quantiles.
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score], CCND2 and DPYS (Table 3) demonstrating that gene
methylation added significant information for predicting
prostate cancer-related death. In contrast to univariate
analysis, where methylation of MAL was most prognos-
tic amongst genes (LR χ2 = 25.4), MAL was not selected
in the final multivariate model. Plausibly, this reflects
the strong correlation of methylation of MAL to both
Gleason score and PSA. A variable that appears strong
in univariate analysis would be eliminated in a multi-
variate analysis by a stronger variable if it adds similar
information to the model due to strong correlation.
Further, this can explain the difference between our re-
sults regarding the prognostic biomarker potential of APC
and GSTP1 and a previous study where prostate cancer-
specific death was also the primary endpoint [21]. Other
factors contributing to the discrepancy may be utilisation
of different methods for assessment of methylation as well
as a different repertoire of clinical variables.
Enhanced expression of protein HSP27 encoded by the
gene HSPB1 was earlier shown to be a reliable biomarker
of poor-outcome cancers [30,31]. Recently, we reported
that HSPB1 methylation and its interaction with Gleason
score has prognostic value and may be of clinical im-
portance for risk stratification of men in the low risk (<7)
Gleason score group [19]. Here, in a multivariate compari-
son with 12 other genes, HSPB1 methylation and its inter-
action term with Gleason score remained important for
risk stratification (Table 3).
Similarly to HSPB1, CCND2 methylation displayed an
HR of 0.86 [95% CI 0.75-0.98] (Table 3) indicating that
higher levels of methylation were associated to lower risk
of prostate cancer death, consistent with the role of acti-
vated CCND2 as an oncogene. Previously, the prognostic
value of CCND2 had been evaluated only with respect
to biochemical reoccurrence and with discordant find-
ings [22,32].
DPYS appeared useful for predicting prostate cancer-
specific mortality in all models where gene methylation
was included (Table 3). Furthermore, the distribution of
methylation showed the largest difference in median
methylation between the two groups of patients (Figure 2).
Although aberrant methylation of DPYS has been reported
by us and others [20,33] this is the first report demonstrat-
ing its prognostic value in prostate cancer.
Extensive research efforts have suggested a number of
candidate biomarkers and biomarker panels, including
PCA3 [34], TMPRSS-ERG [35], Ki-67 [36], and CCP
score [37] to improve the clinical management of pros-
tate cancer. Ideally, a biomarker detected by molecular
testing of bodily fluids is necessary to avoid intrusive
examinations and potentially harmful biopsies. There-
fore, we compared differences in survival prediction
capabilities between a model based on the current
clinical reference standard and models that excluded
Gleason score but were based on PSA and molecular
epigenetic variables that may be obtained from a serum
or urine test. A model including PSA, and methylation
of DPYS, HSPB1, MAL and TIG1 was better at predict-
ing prostate cancer-related mortality than a model
based only on gene methylation (Table 3). Significance
of TIG1 methylation for mortality prediction was iden-
tified only in the absence of Gleason score, probably
because of the strong correlation between these vari-
ables. A recent report supports the prognostic value of
TIG1 methylation [23]. Comparing the PSA-Gleason
score with PSA-gene methylation model, a similar pro-
portion of men were classed in the low, medium and
high risk groups (Figure 3). Furthermore, the propor-
tion of men who died in each of the groups (Additional
file 1: Table S1) showed a modest decrease in sensitivity
of the PSA-gene model compared to the PSA-Gleason
model; however, specificity was similar, thus prompting
future efforts to assessment of DNA methylation in
body fluids. Although TURP is not the standard modal-
ity for the diagnosis of prostate cancer, the use of
TAPG TURP specimens allowed us to assemble a
unique cohort of untreated men with prostate cancer
with up to 20 years of follow-up and thereby study the
association of DNA methylation to death from prostate
cancer. To eliminate any potential bias introduced by use
of TURP tissues, validation of the current PSA and gene
methylation model is needed in a cohort comprising of
needle biopsies.
Conclusions
Multivariate analysis indicated that methylation of genes
DPYS, CCND2 and HSPB1 added significant prognostic
information and may allow more accurate prediction
of men who can be safely managed by active surveil-
lance. Also, development of a test based upon methyla-
tion of DPYS, HSPB1, MAL and TIG1 complementing
use of PSA may improve identification of men who re-
quire a biopsy. Assays measuring methylation of MAL,
TIG1, HSPB1, CCND2, and DPYS have potential to ac-
curately stratify early prostate cancers and thereafter
to manage affected patients in a biologically appropri-
ate manner.
Additional file
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